Company News

Share this article:

Wyeth and Catalyst Biosciences announced a worldwide collaboration for the discovery, development and commercialization of Factor Vlla products to treat hemophilia and other bleeding conditions. The deal included an upfront payment of $21 million, and total payments “could exceed $500 million,” according to the statement. Wyeth will be responsible for the manufacturing and commercialization of products resulting from the collaboration, including CB 813, an investigational candidate for the treatment of acute bleeding in patients with hemophilia.

A jury awarded J&J's Centocor Ortho Biotech $1.67 billion in a patent infringement suit against Abbott Laboratories. The patent in question was an anti-TNF class of arthritis treatments, co-owned by New York University and Centocor, according to the release. Abbott's drug Humira (adalimumab), which had sales in the billions last year, was found to infringe.

Keltman Pharmaceuticals has contracted inVentiv Selling Solutions to provide a sales team that will supplement the Flowood, MS-based wholesale pharma firm's in-house  team, maintaining in-office medicine dispensing systems for physicians.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.